Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients

HIGHLIGHTS

• who: G. Montes Diaz from the (Sittard, The Netherlands), Rehabilitation and MS-Center (Overpelt, Belgium) and Biomedical Research Institute (Diepenbeek, Belgium)All experimental protocols and methods were conducted in accordance with institutional guidelines and regulations and was approved by the institutes' ethics committees (METC14-T-96, .143/ neuro15.12) and all study subjects gave written informed consent. For the follow-up study, peripheral blood was collected before, after , m and , m of DMF treatment. Clinical outcome measures including the Expanded Disability Status Scale (EDSS) and the Fatigue Scale for Motor and Cognitive Functions (FSMC) were analyzed. Furthermore . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.